8.1 Transfusion Medicine: Blood Typing, Crossmatching & Component Therapy

Transfusion Medicine: Blood Typing, Crossmatching & Component Therapy

Transfusion medicine is a critical cornerstone of veterinary emergency and critical care (ECC). The administration of whole blood and blood components can be lifesaving in cases of acute hemorrhagic shock, severe immune-mediated hemolysis, coagulopathies, and thrombocytopenic bleeding. However, blood products represent biologically active tissue transplants that carry substantial risks of immunologic destruction, infectious disease transmission, and fatal hemodynamic overload. Advanced emergency and critical care veterinary nurses must master erythrocyte antigen systems, crossmatching methodologies, component pharmacology, dosage calculations, and the early recognition of adverse transfusion reactions.

1. Canine Blood Groups & Antigen Systems

Canine erythrocyte surfaces express a variety of genetically determined protein and glycolipid markers designated under the Dog Erythrocyte Antigen (DEA) system. Recognized antigens include DEA 1.1, 1.2, 3, 4, 5, and 7, alongside newer non-DEA blood group antigens such as Dal and Kai 1 / Kai 2.

[Canine Red Blood Cell Antigen Systems]
   ┌─────────────────────────────────────────────────────────────┐
   │  DEA 1.1 (Most Antigenic / Strongest Hemolysin/Agglutinin)  │
   │  DEA 1.2 (Moderately Antigenic)                             │
   │  DEA 3, 5, 7 (Induce Delayed Transfusion Reactions/Hemolysis│
   │  DEA 4 (High-Frequency Antigen / >98% Canine Population)    │
   │  Dal Antigen (Deficient in Dalmatians & Dobermans)          │
   │  Kai 1 / Kai 2 Antigens                                     │
   └─────────────────────────────────────────────────────────────┘

The DEA System & Clinical Significance

• DEA 1.1 and DEA 1.2: DEA 1.1 is by far the most clinically significant and immunogenic antigen in dogs. Dogs that are DEA 1.1-negative do not possess naturally occurring anti-DEA 1.1 alloantibodies. However, if a DEA 1.1-negative dog is transfused with DEA 1.1-positive blood, it will develop high titers of anti-DEA 1.1 antibodies within 7 to 14 days (alloimmunization). A subsequent transfusion of DEA 1.1-positive blood will trigger a catastrophic, acute intravascular hemolytic transfusion reaction.
• DEA 3, 5, and 7: These antigens can stimulate naturally occurring or acquired antibodies that primarily cause delayed extravascular hemolysis and shortened transfused erythrocyte survival time.
• DEA 4: Present on erythrocytes of >98% of the canine population. Because virtually all dogs express DEA 4, antibodies against DEA 4 are exceedingly rare.
• The "Universal Donor" Profile: A true universal canine donor is negative for DEA 1.1, DEA 1.2, and DEA 7, and positive for DEA 4 (often termed "DEA 4 only"). In commercial blood banking, screening for DEA 1.1 negativity is the minimum standard.

Novel Antigens: Dal and Kai

• Dal Antigen: A high-frequency antigen present in most dogs. Certain breeds—most notably Dalmatians, Doberman Pinschers, and Shih Tzus—can be Dal-negative. A Dal-negative dog sensitized by a previous transfusion will destroy Dal-positive blood rapidly.
• Kai Antigens (Kai 1 and Kai 2): Recently discovered erythrocyte surface markers that explain acute hemolytic incompatibilities occurring in DEA 1-matched dogs.

2. Feline Blood Groups: The AB System & The Mik Antigen

Unlike dogs, cats possess potent, naturally occurring alloantibodies (isoantibodies) without prior blood exposure. Consequently, blood typing is strictly mandatory before administering even a single milliliter of blood to a feline patient.

The Mik Antigen

In 2007, an additional red blood cell antigen designated Mik was identified. Mik-negative cats possess naturally occurring anti-Mik alloantibodies. A Mik-negative cat receiving Mik-positive blood (even when fully AB-type matched) can suffer a severe, life-threatening acute hemolytic transfusion reaction. This makes pre-transfusion crossmatching essential in all feline transfusion candidates.

3. Major vs. Minor Crossmatching Protocols

While blood typing identifies specific erythrocyte antigens (e.g., DEA 1.1 or Type A/B), crossmatching determines serological compatibility between an individual donor and recipient, detecting all agglutinating and hemolyzing alloantibodies.

Major vs. Minor Crossmatch Definitions

• Major Crossmatch: Donor Red Blood Cells + Recipient Plasma/Serum
  • Clinical Purpose: Detects antibodies in the recipient's plasma directed against the donor's red blood cells. A positive (incompatible) major crossmatch predicts acute, life-threatening destruction of the transfused donor cells.
• Minor Crossmatch: Donor Plasma/Serum + Recipient Red Blood Cells
  • Clinical Purpose: Detects antibodies in the donor's plasma directed against the recipient's red blood cells. Significant when administering plasma-rich products (Whole Blood, Fresh Frozen Plasma) in large volumes.
• Autocontrols (Controls):
  • Recipient Control: Recipient RBCs + Recipient Plasma (differentiates autoagglutination/autoantibodies from alloantibodies).
  • Donor Control: Donor RBCs + Donor Plasma (rules out donor autoagglutination).

[Crossmatch Testing Matrix]
                  DONOR                   RECIPIENT
         ┌─────────────────────┐   ┌─────────────────────┐
         │  RBCs       Plasma  │   │  RBCs       Plasma  │
         └───┬───────────┬─────┘   └───┬───────────┬─────┘
             │           │             │           │
             │           └─────────────┼────────┐  │
             ▼                         ▼        ▼  ▼
       [MAJOR CROSSMATCH]        [MINOR CROSSMATCH]
       Donor RBCs +               Donor Plasma +
       Recipient Plasma           Recipient RBCs

Indications for Mandatory Crossmatching

1. Any dog that has received a blood transfusion more than 4 to 7 days prior (alloantibodies develop within 1–2 weeks of first exposure).
2. Any dog with an unknown transfusion history.
3. Any feline transfusion recipient (to detect Mik or non-AB incompatibilities).
4. Any patient showing evidence of immune-mediated hemolytic anemia (IMHA) with persistent autoagglutination.

4. Blood Components: Indications, Storage & Dosing Formulas

Modern transfusion medicine advocates component therapy—administering only the specific cellular or plasma fraction required by the patient to maximize donor utility and minimize volume overload.

Blood Component Dosing Formulas

1. Packed Red Blood Cells (pRBCs) Required Volume Formula

$\text{Volume of pRBCs (mL)} = \text{Body Weight (kg)} \times K \times \left(\frac{\text{Desired PCV} - \text{Recipient Current PCV}}{\text{Donor Unit PCV}}\right)$

• Canine Blood Volume Constant ($K$): $90\text{ mL/kg}$
• Feline Blood Volume Constant ($K$): $60\text{ mL/kg}$
• Donor Unit PCV: Typically assumed to be $70\text{–}80%$ (0.70–0.80) for pRBCs, or $40\text{–}45%$ for Whole Blood.

2. Clinical Rule of Thumb

• $1\text{ mL/kg}$ of pRBCs (or $2\text{ mL/kg}$ of Whole Blood) raises the recipient's PCV by $1%$ (assuming a donor PCV of ~70–80% for pRBCs and ~40% for WB).
• FFP / FP Dosage: $10\text{–}20\text{ mL/kg IV}$, titrated to coagulation profile normalization (e.g., PT/aPTT).
• Cryoprecipitate Dosage: $1\text{ unit per }10\text{ kg body weight}$ (or $2\text{–}5\text{ mL/kg IV}$).

5. Administration Protocols & Critical Nursing Monitoring

Safe blood product administration requires strict adherence to sterile handling, microfiltration, compatible fluid selection, and structured rate escalation.

Blood Administration Guidelines

1. In-Line Microfiltration: Always administer blood products through a standard blood administration set containing a 170–260 micron filter to capture cellular microaggregates, platelet clumps, and fibrin strands. For feline and pediatric volumes (<50 mL), specialized blood filter syringes (e.g., Hemo-Nate 18-micron filter) or syringe-in-line filters are utilized.
2. Strict Fluid Compatibility:
   • Compatible: 0.9% Sodium Chloride (0.9% NaCl) is the only fluid universally compatible with blood products.
   • CONTRAINDICATED: Calcium-Containing Fluids (e.g., Lactated Ringer's Solution - LRS): Calcium binds and overwhelms the citrate anticoagulant in the blood bag, inducing massive clot formation within the administration set and IV catheter.
   • CONTRAINDICATED: Hypotonic Solutions (e.g., 5% Dextrose, 0.45% NaCl, Sterile Water): Cause rapid osmotic influx into red blood cells, leading to severe in-line hemolysis.
   • No Concurrent Drug Additions: Never co-infuse medications through the same IV line as blood.
3. Rate Escalation Protocol:
   • Initial 15–30 Minutes (Test Rate): Infuse slowly at $0.25\text{–}0.5\text{ mL/kg/hr}$. The veterinary nurse must remain at the patient's side, recording baseline vitals and monitoring continuously for signs of acute reaction.
   • Maintenance Rate: If no adverse signs occur, increase the infusion rate to deliver the remaining volume over 2 to 4 hours (typically $5\text{–}10\text{ mL/kg/hr}$ in normovolemic patients; up to shock rates in active exsanguination).
4. The 4-Hour Time Limit: A blood product infusion must be completed within 4 hours of breaking the sterile seal and warming to room temperature. Beyond 4 hours, room-temperature blood products support rapid bacterial multiplication and endotoxin generation.

[Blood Administration Timeline & Nursing Surveillance]
  0 min          15-30 min                                 4 Hours Max
  ├──────────────┼─────────────────────────────────────────────┤
  │ Slow Test    │ Ramp up to calculated rate (5-10 mL/kg/hr)  │ Finish & Flush
  │ 0.25-0.5     │ Monitor Vitals q30min                       │ Discard bag
  │ mL/kg/hr     │ (T, HR, RR, BP, CRT, MM, Plasma color)      │

6. Transfusion Reactions: Classification, Recognition & Emergency Management

Adverse transfusion events are divided into acute (<24 hours of initiation) and delayed (>24 hours to weeks), and subdivided into immunologic and non-immunologic etiologies.

Acute Immunologic Reactions

• Acute Hemolytic Transfusion Reaction (AHTR): Type II hypersensitivity caused by pre-formed recipient antibodies attacking donor red cells (e.g., Type B cat receiving Type A blood; DEA 1.1-sensitized dog receiving DEA 1.1+ blood). Manifests with fever, tachycardia, tachypnea, severe hypotension, vomiting, hemoglobinemia, hemoglobinuria, DIC, and acute renal failure. Action: Stop transfusion immediately, maintain IV access, administer aggressive crystalloids, colloids, and vasopressors.
• Febrile Non-Hemolytic Transfusion Reaction (FNHTR): The most common transfusion reaction; caused by recipient antibodies reacting against donor white blood cells or accumulating cytokines in stored blood. Manifests as a temperature elevation of >1–2°F (>0.5–1.0°C) above baseline without evidence of hemolysis. Action: Temporarily stop transfusion; if fever resolves and no hemolysis is noted, restart at a slower rate; consider antipyretics.
• Allergic & Anaphylactic Reactions: Type I hypersensitivity mediated by IgE against donor plasma proteins. Symptoms include urticaria (hives), pruritus, facial angioedema, erythema, vomiting, and, in severe cases, bronchospasm and anaphylactic collapse. Action: Pause transfusion, administer Diphenhydramine ($1\text{–}2\text{ mg/kg IM}$) $\pm$ Dexamethasone SP ($0.1\text{–}0.2\text{ mg/kg IV}$), Epinephrine if anaphylactic.
• Transfusion-Related Acute Lung Injury (TRALI): Donor antibodies activate recipient neutrophils within pulmonary microvasculature, causing non-cardiogenic pulmonary edema within 6 hours. Characterized by severe acute dyspnea, hypoxemia, bilaterally symmetric diffuse lung crackles, and normal left atrial pressure. Action: Terminate transfusion, provide aggressive oxygen therapy and positive-pressure ventilation.

Acute Non-Immunologic Reactions

• Transfusion-Associated Circulatory Overload (TACO): Volume overload resulting from excessive rate or volume of infusion, especially in patients with occult myocardial disease, renal failure, or chronic normovolemic anemia. Signs include tachypnea, orthopnea, serous nasal discharge, coughing, pulmonary crackles, cyanosis, and hypertension. Action: Stop transfusion immediately, provide supplemental oxygen, administer Furosemide ($1\text{–}2\text{ mg/kg IV}$).
• Citrate Toxicity & Hypocalcemia: Citrate anticoagulant in blood products chelates recipient ionized calcium ($i\text{Ca}^{2+}$). Commonly seen during massive transfusion (>1 blood volume in 24h) or in patients with liver dysfunction unable to metabolize citrate. Signs include muscle tremors, facial twitching, tetany, weakness, prolonged QT interval on ECG, and hypotension. Action: Slow transfusion rate, administer 10% Calcium Gluconate ($0.5\text{–}1.0\text{ mL/kg IV slow over 15–20 minutes}$) with continuous ECG monitoring.
• Hypothermia: Rapid infusion of refrigerated blood products cools core body temperature, impairing platelet function and drug metabolism. Action: Use warm water fluid warmers (never microwave or immerse unsealed blood bags in boiling water).
• Bacterial Contamination & Sepsis: Transfusion of contaminated units causes acute septic shock and high fever.